Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Fizazi criticizes PROTEASE's control arm because it was not surgery alone; both arms received neoadjuvant ADT, which drives postoperative PSA to zero. That prevents clinicians from using PSA to trigger adjuvant radiation or intensification, a key limitation for translating the trial into practice. He calls this a design criticism.

Related Insights

Unlike in breast or bladder cancer, the significant improvement in pathologic response in the PROTEUS trial did not translate to a similarly impressive benefit in metastasis-free survival. This disconnect suggests that eliminating tumor in the prostate specimen is not a reliable surrogate for long-term outcomes in this disease setting.

The PROTEUS trial used ADT plus surgery as its control, not surgery alone. This design is controversial because many patients choose surgery specifically to avoid systemic therapies like ADT. This complicates the interpretation of results and reflects a disconnect from real-world patient motivations.

The standard practice of using rising PSA to trigger early salvage radiotherapy after surgery is complicated by the PROTEUS protocol's neoadjuvant hormone therapy. This approach muddies the interpretation of biochemical recurrence, making it difficult for clinicians to know when or if to intervene with salvage treatment, potentially leading to worse outcomes.

The control arm in the EMBARK study was blinded to PSA results, preventing physicians from intervening with standard-of-care AR antagonists at PSA progression. This design likely delayed subsequent effective therapies, making the control arm underperform and potentially exaggerating the overall survival benefit of the experimental arms.

The highly anticipated PROTEUS trial is testing a new drug combination against a control arm of ADT plus placebo for prostatectomy patients. This design is controversial because ADT is not standard care in this setting, raising concerns that a positive result could be driven by a suboptimal control arm.

An expert expressed disappointment with Lutetium's efficacy in the metastatic hormone-sensitive setting, suggesting its benefit is lower than expected. A potential flaw in trial design was starting hormonal agents first, which can lower PSMA expression, thereby potentially reducing the radioligand's target and diminishing its therapeutic effect.

Despite meeting its primary endpoint, the PROTEUS trial provides no validated biomarkers to identify which patients actually benefit from the intensified therapy. This lack of a predictive signature means applying the results in the clinic amounts to uniform escalation, likely overtreating many patients for an uncertain benefit, making it difficult to implement.

Fizazi says PROTEASE was positive for metastasis-free survival only after investigators amended the protocol to include PSMA PET; the original conventional-imaging endpoint had a p-value above 0.05. That split interpretation—positive by amended endpoint, not by original—fuels debate about whether to intensify high-risk localized disease. He notes opinions remain divided among clinicians.

The trial's principal investigator initially designed a control arm of prostatectomy alone. However, to maintain blinding and prevent patients from dropping out over a multi-year follow-up, a compromise was made to use ADT plus placebo, highlighting the pragmatic trade-offs required in large-scale clinical trials.

Expert analysis reveals a key weakness in many Lutetium-PSMA trials: the choice of the control arm. By comparing the novel therapy against a less-than-optimal standard of care, the trials may have been designed for an "easy win," dampening expert enthusiasm and raising questions about its true superiority over other potent hormonal therapies.